Skip to main content
. Author manuscript; available in PMC: 2020 Aug 26.
Published in final edited form as: Aliment Pharmacol Ther. 2012 Mar 26;35(9):1027–1035. doi: 10.1111/j.1365-2036.2012.05059.x

Table 1 ∣.

Baseline demographic and clinical characteristics

Feature Lamivudine &
adefovir
(n = 22)		 Adefovir
(n = 19)
Age (years)* 46 (14) 45 (13)
Gender, male 16 (73%) 18 (95%)
Race
 White 9 (41%) 8 (42%)
 Asian 9 (41%) 10 (53%)
 Black 4 (18%) 1 (5%)
 Treatment-naïve 17 (77%) 14 (74%)
Genotype
 A 11 (50%) 7 (37%)
 B 5 (23%) 3 (16%)
 C 2 (9%) 7 (37%)
 D 2 (9%) 2 (10%)
 A/G 2 (9%) 0 (0%)
 ALT (U/L)* 183 (250) 87 (56)
 HBeAg-positive 17 (77%) 14 (74%)
 HBV DNA (Log10 Copies/mL)* 8.1 (1.3) 7.8 (1.6)
Liver histology
 Total HAI* 8.1 (2.7) 7.9 (2.4)
 Ishak Fibrosis Score* 3.3 (1.7) 2.4 (1.5)
 Cirrhosis (%) 5 (23) 2 (11)

HAI, histology activity index.

*

Mean (s.d.).